Copyright
©The Author(s) 2021.
World J Clin Oncol. Sep 24, 2021; 12(9): 800-807
Published online Sep 24, 2021. doi: 10.5306/wjco.v12.i9.800
Published online Sep 24, 2021. doi: 10.5306/wjco.v12.i9.800
Table 1 Salient features of 88 patients with Hodgkin´s lymphoma
| Sex | Women | 37 (42) |
| Men | 51 (57.9) | |
| Age, yr | Median 29 (range: 5-73) | |
| Type | Nodular sclerosing | 62 (70) |
| Mixed cellularity | 19 (21.5) | |
| Lymphocyte depleted | 2 (2.2) | |
| Lymphocyte predominant | 1 (1.1) | |
| Stage | Stage I | 5 (5.6) |
| Stage II | 48 (54.5) | |
| Stage III | 19 (1.5) | |
| Stage IV | 16 (18.1) | |
Table 2 Salient features of patients who developed a secondary malignancy after the treatment of lymphoma
| Neoplasm | Age | Sex | Type | Stage | Treatment | HSCT | Time1, mo | |
| 1 | Tongue epidermoid carcinoma | 32 | M | Nodular sclerosing | I | Radiotherapy | No | 58 |
| 2 | Liver adenocarcinoma | 22 | F | Nodularsclerosing | III | MOPP | No | 97 |
| 3 | Breast cancer | 38 | F | Mixed cellularity | III | ABVD | No | 150 |
| 4 | NK/T-cell lymphoma | 15 | M | Nodular sclerosing | IV | ABVD | Autologous | 18 |
| 5 | Breast cancer | 23 | F | Nodular sclerosing | III | AVBD | Autologous | 59 |
- Citation: Sánchez-Valledor LF, Habermann TM, Murrieta-Alvarez I, Córdova-Ramírez AC, Rivera-Álvarez M, León-Peña A, Cantero-Fortiz Y, Olivares-Gazca JC, Ruiz-Delgado GJ, Ruiz-Argüelles GJ. Long-term results of the treatment of Hodgkin’s lymphoma in a resource-constrained setting: Real-world data from a single center. World J Clin Oncol 2021; 12(9): 800-807
- URL: https://www.wjgnet.com/2218-4333/full/v12/i9/800.htm
- DOI: https://dx.doi.org/10.5306/wjco.v12.i9.800
